Maupiti – Polynesia

PSST and ETT support

SOGC/GOC Clinical Guideline #408, January 2021

  • PSTT and ETT are distinguished by their slow growth, late metastasis and increased resistance to chemotherapy.
  • The level of hCG secreted by these tumors is lower, because they arise from the intermediate trophoblast.
  • Stage I patients should be offered surgical treatment that includes simple hysterectomy with consideration of ovarian preservation. The need for lymph node dissection remains uncertain (5.9% N+).
  • Adjuvant chemotherapy EMA-EP or TP/TE should be offered, although the likelihood of response is low, to patients with the following risk factors:
  • History of pregnancy more than 48 months
  • FIGO stage II to IV
  • Consolidation chemotherapy after normalization of serum hCG level continues for 8 weeks (4 cycles).
  • Resection may be necessary for isolated persistent tumor sites.
  • Long-term follow-up may be necessary in case of PSTT or ETT.

2021. Guideline No. 408: Management of Gestational Trophoblastic Diseases. Eiriksson L, Dean E, Sebastianelli A, Salvador S, Comeau R, Jang JH, Bouchard-Fortier G, Osborne R, Sauthier Ph. J Obstet Gynaecol Can;43(1):91-105.

Modified on 12/23/2023